Education
About Us
Working with TipRanks
Follow Us
Senti Biosciences (SNTI)
NASDAQ:SNTI
SNTI Analyst Ratings
Strong Buy
3 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SNTI Stock 12 Month Forecast
Average Price Target
$12.50
▲(854.20% Upside)
| Highest Price Target$13.00 | Average Price Target$12.50 | Lowest Price Target$12.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Leerink Partners
Buy
―
Reiterated
12/15/25
Promising Potential of SENTI-202 in Treating Acute Myeloid Leukemia: A Buy Recommendation Despite Financial RisksWe believe that SENTI-202’s Ph 1 update in r/r AML was encouraging and de-risks more substantive investment in the program, including the company’s planned pivotal trial set for initiation in 2H26, pending funding. Though we have some lingering uncertainty in SENTI-202’s efficacy signal simply because of the small sample size of the dataset (n=18 evaluable, n=12 at RP2D), SENTI-202’s dose expansion update validated the therapy’s potential and contribution of the company’s unique logic- gate-CARs. First, SENTI-202 maintained a promising emerging efficacy signal that compares favorably to available r/r AML treatment options, including a robust depth-of-response with high rates of MRD-negativity, competitive duration-of-response, and a capacity to successfully transition patients transplant—all leading indicators of strong overall survival (OS).
H.C. Wainwright
$12
Buy
816.03%
Upside
Reiterated
12/10/25
Chardan Capital
$12→$13
Buy
892.37%
Upside
Reiterated
12/09/25
Laidlaw
$5
Buy
281.68%
Upside
Initiated
06/06/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Leerink Partners
Buy
―
Reiterated
12/15/25
Promising Potential of SENTI-202 in Treating Acute Myeloid Leukemia: A Buy Recommendation Despite Financial RisksWe believe that SENTI-202’s Ph 1 update in r/r AML was encouraging and de-risks more substantive investment in the program, including the company’s planned pivotal trial set for initiation in 2H26, pending funding. Though we have some lingering uncertainty in SENTI-202’s efficacy signal simply because of the small sample size of the dataset (n=18 evaluable, n=12 at RP2D), SENTI-202’s dose expansion update validated the therapy’s potential and contribution of the company’s unique logic- gate-CARs. First, SENTI-202 maintained a promising emerging efficacy signal that compares favorably to available r/r AML treatment options, including a robust depth-of-response with high rates of MRD-negativity, competitive duration-of-response, and a capacity to successfully transition patients transplant—all leading indicators of strong overall survival (OS).
H.C. Wainwright
$12
Buy
816.03%
Upside
Reiterated
12/10/25
Chardan Capital
$12→$13
Buy
892.37%
Upside
Reiterated
12/09/25
Laidlaw
$5
Buy
281.68%
Upside
Initiated
06/06/25
Best Analysts Covering Senti Biosciences
1 Month
xxx
Success Rate
3/11 ratings generated profit
Average Return
+5.74%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 27.27% of your transactions generating a profit, with an average return of +5.74% per trade.
3 Months
xxx
Success Rate
2/11 ratings generated profit
Average Return
-12.22%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 18.18% of your transactions generating a profit, with an average return of -12.22% per trade.
1 Year
Success Rate
0/11 ratings generated profit
Average Return
-48.49%
reiterated a buy rating 7 days ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -48.49% per trade.
2 Years
xxx
Success Rate
0/11 ratings generated profit
Average Return
-52.38%
reiterated a xxx
rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -52.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SNTI Analyst Recommendation Trends
Rating
Jun 25
Aug 25
Oct 25
Nov 25
Dec 25
Strong Buy
1
2
2
5
6
Buy
1
1
1
0
0
Hold
3
0
0
0
0
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
3
3
5
6
Each month's total comprises the sum of three months' worth of ratings.
SNTI Financial Forecast
SNTI Stock Forecast FAQ
What is SNTI’s average 12-month price target, according to analysts?
Based on analyst ratings, Senti Biosciences’s 12-month average price target is 12.50.
What is SNTI’s upside potential, based on the analysts’ average price target?
Senti Biosciences has 854.20% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SNTI a Buy, Sell or Hold?
Senti Biosciences has a consensus rating of Strong Buy which is based on 3 buy ratings, 0 hold ratings and 0 sell ratings.
What is Senti Biosciences’s price target?
The average price target for Senti Biosciences is 12.50. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $13.00 ,the lowest forecast is $12.00. The average price target represents 854.20% Increase from the current price of $1.31.
The highest analyst price target is $13.00 ,the lowest forecast is $12.00. The average price target represents 854.20% Increase from the current price of $1.31.
What do analysts say about Senti Biosciences?
Senti Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
How can I buy shares of SNTI?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.